Skip to main content
AEMD logo

AEMD · Aethlon Medical Inc

Track AEMD — free
$4.84 -0.27 (-5.28%)
Market Cap
$7.78M
Shares
1.61M
Volume · Nov 19 20.26K Avg daily vol (3M) 2.52M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.84 Open$5.06 Day$4.80–5.09 52W close$1.43–24.20 Avg vol 30d45K Short int43K · 2.7% of shares · 1.0d Short vol29% Last earningsAug 13, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 12

Latest documents

2026
Nov 16
Current report 8-K
North Immunology updates investor presentation for pending Aethlon merger

Aethlon Medical furnished an updated investor presentation from North Immunology, its merger target under the September 17, 2026 agreement. It details the NOR-101 IL-13 x IL-18 bispecific antibody, Phase 1a start in Q1 2027, and an anticipated $180M private placement.

Regulation FD disclosure
5 source passages
on September 17, 2026, Aethlon Medical, Inc., a Nevada corporation (the “Company”), Nighthawk Merger Sub Corp. On November 16, 2026, North Immunology updated information reflected in an investor presentation NOR - 101 is a Half - life Extended Anti - IL - 13 x IL - 18 Bispecific Antibody Target Phase 1a Start: Q1 2027 Anticipated $180M PIPE raise provides cash into 2H 2028 Open the document at this passage
Nov 12
Quarterly report 10-Q FY2027 Q2, ended Sep 30
North Immunology merger expected in first calendar quarter 2027

Aethlon Medical agreed to merge with North Immunology, a two-step transaction expected to close in first calendar quarter 2027. The six-month net loss rose to $4,165,000, while cash was $6,486,639 as of September 30, 2026.

Net loss $2.62M Diluted EPS -$2.60
Read from the MD&A section
4 source passages
On September 17, 2026, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with North Immunology, Inc. (“North Immunology”) and two wholly owned subsidiaries of the Company, pursuant to which the parties agreed to effect a two-step merger transaction (the “Merger”). The Merger is currently expected to close in the first calendar quarter 2027, subject to required stockholder approvals, completion of the contemplated financing, effectiveness of the applicable registration statement, approval of the combined company’s Nasdaq listing application and satisfaction of other closing conditions. As a result of the changes in expenses noted above, our net loss increased from approximately $3,249,000 in the six months ended September 30, 2025, to $4,165,000 in the six months ended September 30, 2026. As of September 30, 2026, we had a cash balance of $6,486,639 and working capital of $5,582,635. Open the document at this passage
Nov 12
Current report 8-K
Proposed merger drives workforce reductions and higher expenses

Aethlon Medical entered a merger agreement with North Immunology on September 17, 2026 and implemented workforce reductions. Cash was approximately $6.5 million as of September 30, 2026; quarterly operating expenses rose 77.2% to approximately $2.7 million.

Financial results, Regulation FD disclosure
4 source passages
On September 17, 2026, we entered into a Plan of Merger and Reorganization (the “Merger Agreement”) with North Immunology, Inc. (“North Immunology”) and two wholly owned subsidiaries of the Company, pursuant to which the parties agreed to effect a two-step merger transaction (the “Merger”). In connection with the proposed Merger we implemented workforce reductions near the end of the second fiscal quarter. Cash and cash equivalents were approximately $6.5 million as of September 30, 2026. Consolidated operating expenses for quarter increased 77.2% to approximately $2.7 million versus approximately $1.5 million in the prior-year quarter. Open the document at this passage
Oct 9
Current report 8-K Events of Oct 7
Charter or bylaw amendment, or fiscal year change

Aethlon Medical, Inc. increased authorized common stock from 20,000,000 shares to 200,000,000 shares, following stockholder approval on October 1, 2026; the amendment became effective on October 7, 2026.

Oct 5
Current report 8-K/A Events of Oct 1
Shareholder vote results

Aethlon Medical, Inc. stockholders did not approve a proposal to authorize 20,000,000 preferred shares because 204,122 votes in favor fell below the required 355,569; the Articles of Incorporation were not amended.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$8.07M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
3.5
Trailing earnings · reciprocal yield 28.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$6.49M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,167.3%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.7%
Latest settlement · 1.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Feb 12, 2026
Q3 FY26

TL;DR. Aethlon advanced its Australian oncology trial and research programs, maintained Nasdaq compliance, and reduced year-to-date operating expenses. The quarter still had higher operating expenses and a larger operating loss, while cash adequacy and investigational-device risks remain concerns; SLAMB also requires regulatory submission and is not expected to benefit the current or next trial.

Bullish
  • + Cohort 2 of the Australian oncology trial is progressing after Cohort 1 showed favorable directional improvements in extracellular vesicle and immune cell numbers.
  • + Year-to-date operating expenses declined 26.9% through continued cost optimization.
  • + Long COVID research findings were published on bioRxiv and submitted for peer review.
  • + The Hemopurifier may provide a pipeline within a single device.
  • + Stavro is evaluating Hemopurifier compatibility with the SLAMB system, which may support broader future use without dialysis equipment or a supervising nephrologist.
  • + The company maintained Nasdaq listing compliance and resolved all prior compliance matters.
Bearish
  • − Fiscal Q3 operating expenses rose 13.6% and the operating loss increased to $2.06 million from $1.81 million.
  • − Interest income declined to $44,000 from $60,000 in the prior-year quarter.
  • − Cash may not support operations for the next 12 months without additional financing, and capital may be unavailable or unfavorable.
  • − The Hemopurifier remains investigational, with its safety and effectiveness not established.
  • − The SLAMB system is not FDA-approved and would require a regulatory submission and additional treatments with the two systems.
  • − SLAMB compatibility work is not expected to benefit the current or next trial.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −33%
below
Price vs 50-day avg −10%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 15%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −7%
trailing
6-month return −60%
trailing
YTD return −65%
this year
Relative strength −54%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.69% of shares out · ▲ +31.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 7-yr range
Squeeze score 60
elevated · 0–100
Fundamentals
Weak
Revenue growth −100%
Y/Y
EPS growth +88%
Y/Y
Free cash flow $-7.0M
Quant / Vol
risk profile
Very High
Volatility 388%
annualized · 1-yr
Max drawdown −94%
past year
ATR 7.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−33% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
15% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.69% of shares out · ▲ +31.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 7-yr range
Price context
position in its 52-week range
Range low $1 Now $5 · 15% Range high $24
vs 200-day avg -33% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AEMD
Aethlon Medical Inc
this stock
$7.78M — -100.0% — 2.7%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
17
% held
32.1%
Net QoQ
+462.3K sh
Top holder
STEMPOINT CAPITAL LP
Held Float
View
Held by Funds
Fund positions
3
View
Short & Settlement
Short Interest Rising
Shares short
43.2K
Days to cover
1.0d
Change
+10.3K sh
View
Short Volume
Short vol %
29%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
2.6K
Value
$14.3K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
34.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-7.2M
EPS diluted
$-53.05
View
Buybacks
Remaining
shares 1.1K
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
31

Aethlon Medical furnished an updated investor presentation from North Immunology, its merger target under the September 17, 2026 agreement. It details the NOR-101 IL-13 x IL-18 bispecific antibody, Phase 1a start in Q1 2027, and an anticipated $180M private placement.

View
Exempt Offerings
Offering
$2.2M
Filed
Dec 23, 2025
View
Earnings & Events
Webcasts
Last webcast
Aug 13, 2026
View
Investor Relations
Latest news
Aethlon Medical Reports Second Qu…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
AEMD -13.3% -6.7% -59.8% -11.0% -65.1%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -7.8% -0.5% -54.2% -5.8% -70.0%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
—
Spent (derived)
—
Remaining
shares 1,091

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 882291 CUSIP 00808Y703 13F (30d) 16 filings 16 filers Visit website Investor relations